ResMed dominates healthcare devices with innovation, recurring revenues, and market leadership. See why we believe RMD stock ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

After reporting robust results, Resmed reckons it won't be subject to US tariffs while the growth of anti-obesity drugs will be a tailwind.

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...

While US President Donald Trump's tariffs have sent global markets into a tailspin, medical technology companies are ...

Morgans senior healthcare analyst Scott Power says healthcare stocks have had a strong start to the latest reporting season.

Reports Q3 revenue $1.3B, consensus $1.28B. “Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line ...

Discover ResMed's Q3 2025 earnings highlights, including 8% revenue growth, margin expansion, new product launches, and strategic investments in ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Wednesday reported fiscal third-quarter profit of $365 million. On a per-share basis, the San Diego-based company said it had profit of $2.48.

Unveiled the findings of our fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscored a widespread global sleep crisis, with people losing an ...

Sleep device maker Resmed claims it is exempt from US President Donald Trump’s new tariffs as it eyes expansion in the ...